NASDAQ:PCRX Pacira BioSciences (PCRX) Stock Price, News & Analysis $23.35 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$23.33 -0.02 (-0.09%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pacira BioSciences Stock (NASDAQ:PCRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pacira BioSciences alerts:Sign Up Key Stats Today's Range$23.24▼$23.7450-Day Range$21.94▼$25.5552-Week Range$18.80▼$27.64Volume857,902 shsAverage Volume618,742 shsMarket Capitalization$918.82 millionP/E Ratio194.60Dividend YieldN/APrice Target$29.40Consensus RatingHold Company Overview Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain. In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control. The company has advanced clinical research in areas such as extended-release meloxicam formulations for soft tissue and orthopedic procedures, aiming to further expand its portfolio of non-opioid pain therapies. Pacira collaborates with healthcare providers and research partners to support clinical trials and to explore potential new indications for its proprietary technologies. Founded in 2006 and headquartered in Parsippany, New Jersey, Pacira BioSciences markets its products throughout the United States and in select international territories. The company emphasizes education and training for healthcare professionals to ensure the safe and effective use of its therapies. Pacira’s operations encompass regulatory affairs, medical affairs, and commercial functions, all dedicated to advancing patient-centered approaches to pain management.AI Generated. May Contain Errors. Read More Pacira BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScorePCRX MarketRank™: Pacira BioSciences scored higher than 68% of companies evaluated by MarketBeat, and ranked 258th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingPacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialPacira BioSciences has a consensus price target of $29.40, representing about 25.9% upside from its current price of $23.35.Amount of Analyst CoveragePacira BioSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pacira BioSciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth39.79% Earnings GrowthEarnings for Pacira BioSciences are expected to grow by 39.79% in the coming year, from $1.91 to $2.67 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 194.60, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 194.60, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.01.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pacira BioSciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.15% of the float of Pacira BioSciences has been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 14.23, which indicates bearish sentiment.Change versus previous monthShort interest in Pacira BioSciences has recently increased by 5.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.37 News SentimentPacira BioSciences has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Pacira BioSciences this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for PCRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $702,610.00 in company stock.Percentage Held by Insiders6.40% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pacira BioSciences' insider trading history. Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCRX Stock News HeadlinesPharmaCorp Announces Definitive Agreement to Acquire PharmaChoice Canada Bannered Pharmacy in OntarioMay 25 at 9:27 AM | globenewswire.comPacira shareholders lobbied by hedge fund board nomineesMay 21, 2026 | seekingalpha.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 25 at 1:00 AM | Paradigm Press (Ad)A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLCMay 21, 2026 | prnewswire.comDOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira BiosciencesMay 20, 2026 | prnewswire.comPacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All StockholdersMay 20, 2026 | globenewswire.comPacira BioSciences: Exparel Still Supports My Original Bull CaseMay 19, 2026 | seekingalpha.comDOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR ...May 13, 2026 | finance.yahoo.comSee More Headlines PCRX Stock Analysis - Frequently Asked Questions How have PCRX shares performed this year? Pacira BioSciences' stock was trading at $25.88 at the beginning of 2026. Since then, PCRX shares have decreased by 9.8% and is now trading at $23.35. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) issued its quarterly earnings data on Thursday, April, 30th. The company reported $0.60 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.61 by $0.01. The business's revenue for the quarter was up 5.0% on a year-over-year basis. Read the conference call transcript. When did Pacira BioSciences IPO? Pacira BioSciences (PCRX) raised $64 million in an IPO on Wednesday, February 2nd 2011. The company issued 4,250,000 shares at $14.00-$16.00 per share. Who are Pacira BioSciences' major shareholders? Top institutional shareholders of Pacira BioSciences include Dimensional Fund Advisors LP (5.24%), Renaissance Technologies LLC (4.64%), Hillsdale Investment Management Inc. (0.84%) and Bank of New York Mellon Corp (0.77%). Insiders that own company stock include Jonathan Slonin, David M Stack, Daryl Gaugler, Frank D Lee, Shawn Cross, Kristen Williams, Roy Winston, Lauren Riker, Charles A Reinhart III, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson and Marcelo Bigal. View institutional ownership trends. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings4/30/2026Today5/25/2026Jefferies Global Healthcare Conference 20266/03/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/08/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PCRX's financial health is in the Green zone, according to TradeSmith. PCRX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PCRX CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees720Year Founded2006Price Target and Rating Average Price Target for Pacira BioSciences$29.40 High Price Target$38.00 Low Price Target$24.00 Potential Upside/Downside+25.9%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.12 Trailing P/E Ratio194.60 Forward P/E Ratio12.23 P/E GrowthN/ANet Income$7.03 million Net Margins0.70% Pretax Margin1.79% Return on Equity10.24% Return on Assets5.47% Debt Debt-to-Equity Ratio0.56 Current Ratio4.73 Quick Ratio3.35 Sales & Book Value Annual Sales$726.41 million Price / Sales1.26 Cash Flow$3.86 per share Price / Cash Flow6.05 Book Value$16.62 per share Price / Book1.40Miscellaneous Outstanding Shares39,350,000Free Float36,830,000Market Cap$918.82 million OptionableOptionable Beta0.32 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:PCRX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
